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A B S T R A C T
Background: 1,25-Dihydroxyvitamin D (1,25-(OH)2D), the hormonal form of vitamin D, is difﬁcult to
measure because of its low circulating levels (pg/mL), and similarity to more abundant metabolites. Here
a fully-automated chemiluminescent assay that accurately and precisely measures 1,25-(OH)2D is
described.
Method: The novel 1,25-(OH)2D assay was conceived based on four pillars: (1) the VDR’s ligand binding
domain (LBD) as a capture molecule; (2) reaction conditions wherein 1,25-(OH)2D favors binding to LBD
vs. the vitamin D binding protein; (3) exploitation of liganded-LBD’s conformational change; (4) a
monoclonal antibody speciﬁc to liganded-LBD. This speciﬁc, conformational, sandwich approach, unique
for automated measurement of haptens, is superior to more cumbersome, conventional competitive
formats.
Results: Accuracy of the 1,25-(OH)2D assay was corroborated by its alignment against LC–MS/MS with ﬁt
Deming regression equations of y = 0.98x + 1.93 (r = 0.92), and y = 1.07x + 3.77 (r = 0.94) for different
methods from Endocrine Sciences, Laboratory Corporation of America1 and the University of
Washington, respectively. Good analytical precision was manifested by its low estimated limit of
quantitation (1.57 pg/mL), average intra-assay imprecision (3.5%CV; range 1.1–4.7%), and average inter-
assay imprecision (4.5%CV; range 3.4–7.2%). Expected and measured recovery values were congruent
(93.4% mean).
Conclusions: The novel 1,25-(OH)2D method exhibited excellent correlation with well validated LC–MS/
MS assays from two laboratories. Signiﬁcantly, its 65 min turn-around time is quicker, and sample
volume smaller (75 ml) than current methods.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The synthesis of vitamin D3 in skin is a two-step process: 7-
dehydrocholesterol is converted to previtamin D3 upon exposure
to UV light; previtamin D3 isomerizes to vitamin D [1]. Vitamin D3
and vitamin D2 (that originates from irradiation of ergosterol) may
also be obtained in the diet. [1]. Upon entry into the circulation,
vitamin D is readily hydroxylated in the liver at carbon-25 to
produce 25-hydroxyvitamin D (25-(OH)D), the major circulating
metabolite [2]. Vitamin D metabolites generally associate with the
vitamin D binding protein (VDBP) to be carried through the
bloodstream [3]. Although 25-(OH)D is inactive itself, its serum
level affords the commonly accepted method for assessing vitamin
D status of patients.
The classical role of vitamin D is the maintenance of plasma
calcium and phosphate at near constant levels for proper
neuromuscular function, bone mineralization, and the prevention
of hypocalcemic tetany [4]. Under physiological conditions where
calcium and phosphate homeostasis is disturbed, 25-(OH)D is
converted in the kidney by 1a-hydroxylase to produce 1a,25-
dihydroxyvitamin D (1,25-(OH)2D), which acts on target organs to
normalize plasma calcium and phosphate [4]. Most, if not all, of
circulating 1,25-(OH)2D is produced in the kidney as revealed by
the extremely low circulating levels in nephrectomized rats [5] or
patients [6].
The functions of 1,25-(OH)2D are mediated through a nuclear
receptor that binds to vitamin D response elements (VDREs) in target
genes to regulate their transcription. The vitamin D receptor (VDR) is
a member of the steroid/thyroid hormone nuclear receptor
superfamily and contains characteristic functional domains includ-
ing the DNA binding domain and the ligand binding domain (LBD)Fig. 1. Speciﬁcity of the 11B4 antibody used in the novel 1,25-(OH)2D assay. A Dual
Polarization Interferometry experiment was performed by coating a 2-channel chip
with the monoclonal antibody 11B4 raised against the liganded LBD. Channel 1 was
injected with LBD-1,25-(OH)2D complex (blue), and channel 2 was injected with
apo-LBD (red). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)[7]. The structure of the LBD was recently solved by NMR studies,
which depict a distinct, ligand-speciﬁc conformational change upon
binding of 1,25-(OH)2D [8].
It has long been established that vitamin D deﬁciency causes
bone diseases such as rickets, osteomalacia, and secondary
hyperparathyroidism, but with the discovery of VDR in non-
classical target tissues, 1,25-(OH)2D is now known to have a
broader spectrum of actions, and has been associated with
increased risks for various chronic diseases including infectious
and autoimmune, diabetes, cancer, cardiovascular ailments,
hypertension and complications during pregnancy [9]. Clinical
studies implicating vitamin D in the forgoing conditions have
been based predominantly upon measurement of 25-(OH)D.
Since 1,25-(OH)2D is the active hormone and does not correlate
with 25-(OH)D status, important relationships have remained
unexplored. Facile measurement of 1,25-(OH)2D has been difﬁcult
due to its extremely low circulating levels (pg/mL) [10]. Current
methods, requiring laborious, sample consumptive, pre-analyti-
cal steps are signiﬁcantly compromised at the low end of their
measuring range because of their intrinsic imprecision [10]. In
this manuscript, a new, fully-automated method for measure-
ment of 1,25-(OH)2D in biological ﬂuids is presented. The novel
assay is accurate, precise throughout the entire assay range, fast,
and requires only 75 ml of sample unencumbered by the need for
pre-analytical enrichment through precipitation and subsequent
reconstitution. The exquisite speciﬁcity and avidity of the VDR for
its substrate was used to produce the ﬁrst sandwich, automated
chemiluminescent assay for a small molecule hapten like 1,25-
(OH)2D.
2. Materials and methods
2.1. Specimens
To evaluate the LIAISON1 XL 1,25-Dihydroxyvitamin D assay in
biological ﬂuids, 78 human serum samples routinely submitted to
Laboratory Corporation of America for 1,25-(OH)2D testing were
anonymized and used to make pools with concentrations covering
the analytical measuring range of the assay and parsed into
multiple aliquots for analysis by multiple methods. The protocol
for this study was determined to be exempt under existing
regulations by the Institutional Review Board.
2.2. Method comparison
Method comparison of 1,25-(OH)2D measurement included
two different LC–MS/MS methods using immune-extraction to
enrich for 1,25-(OH)2D as a pre-analytical step; the ﬁrst
method was from Endocrine Sciences, Laboratory Corporation
of America (Calabasas Hills, CA), and the second LC–MS/MS
analysis was performed at the University of Washington and
is outlined by Strathmann et al. [11]. A commercially
available immunoassay (Method A) was also compared to the
LIAISON1 XL 1,25-dihydroxyvitamin D assay (DiaSorin, Still-
water, MN).
Fig. 2. Schematic of the novel 1,25-(OH)2D assay. An overview of the components, incubations [3], and wash steps [2] of the fully-automated assay to be run on a LIAISON1XL
instrument. Sample size required is 75 ml, and time to ﬁrst result is 65 min. PMP: paramagnetic particles; ABEI: isoluminol derivative.
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Imprecision, recovery, limit of quantitation (LOQ), limit of blank
(LOB), linearity, and analytical speciﬁcity were evaluated according
to CLSI guidelines. The reference range was veriﬁed on a subset of
41 apparently healthy blood donor volunteers.
2.4. Statistical analysis
All data were analyzed using EP Evaluator1 (Data Innovations,
LLC). Linear regressions were performed by regular and Deming
methods using Analyse-itTM for Microsoft Excel.
2.5. The novel 1,25-dihydroxyvitamin D assay
Specimens were tested to evaluate the novel 1,25-(OH)2D
method using the CE marked, Investigational Use Only DiaSorin
LIAISON1 XL 1,25-Dihydroxyvitamin D assay (Stillwater, MN). The
novelty and efﬁcacy of this 1,25-(OH)2D assay depend upon four
key design pillars: (1) use of the ligand binding domain (LBD) of the
VDR as a capture molecule; (2) use of reaction conditions where
binding of 1,25-(OH)2D to the LBD is favored over binding to the
VDBP by 200-fold. At those same conditions, inactive metabolites
of vitamin D, including 25(OH)D, 24,25-dihydroxyvitamin D, and
25,26-dihydroxyvitamin D, preferentially bind to the VDBP by 10-
100-fold creating a binding differential of 2000-20,000-fold
(which greatly minimizes interference from the 100-1000-fold
higher physiological concentrations of inactive metabolites
compared to 1,25(OH)2D); (3) exploitation of the LBD conforma-
tional change induced upon 1,25-(OH)2D binding as delineated by
NMR analysis [8]; (4) the use of a monoclonal antibody that
selectively recognizes the unique LBD conformation produced
when 1,25-(OH)2D is bound to the LBD.
Monoclonal antibodies (Mab) against the LBD-1,25-(OH)2D
complex screened by ELISA were characterized by Dual Polariza-
tion Interferometry, DPI (AnaLight 4D, Farﬁeld Group, UK). DPI
measures real time binding events on the face of a biosensor chip.
The selected clone 11B4 accumulated 8.9 ng of the LBD-1,25-(OH)2D complex within the ﬁrst 400 sec as opposed to a minimal
amount of unbound, control apo-LBD during the same time frame
(Fig. 1), showing the high speciﬁcity of the 11B4 Mab for the LBD-
1,25-(OH)2D complex.
Fig. 2 depicts the DiaSorin LIAISON1 XL 1,25-Dihydroxy-
vitamin D assay’s mechanics. First, 75 ml of sample are incubated
with the ligand binding domain (LBD) of the VDR. Under
incubation conditions, the transfer of 1,25-(OH)2D from VDBP
to the LBD is greatly favored. Second, coated magnetic beads
with Mab 11B4, speciﬁc to the LBD-1,25-(OH)2D complex
conformation, are added to the reaction mixture. Following
incubation, unbound materials (unbound-LBD, VDPB, inactive
vitamin D metabolites) are removed with a wash cycle. Finally in
step 3, conjugate (Mab with a chemiluminescent label) speciﬁc
to a distal epitope of the LBD is added, and upon binding to the
solid phase bound LBD-1,25-(OH)2D complex a sandwich is
completed.
Following a second wash step to remove unbound conjugate,
starter reagents are added triggering a chemiluminescent reaction.
The light ﬂash emitted, measured by a photomultiplier tube,
affords a signal directly proportional to the amount of 1,25-(OH)2D
present in the sample.
3. Results
3.1. Accuracy
A method comparison was performed on 78 patient samples.
Fig. 3 shows a Deming regression ﬁt (left) and an Altman–Bland
difference plot (right) for each method pairing. In Fig. 3A, excellent
agreement is observed for the LIAISON1 XL 1,25-Dihydroxyvita-
min D assay against the Endocrine Sciences, Laboratory Corpora-
tion of America reference LC–MS/MS, with correlation coefﬁcient
R = 0.92, slope of 0.98 (0.90–1.06 95% CI) and an intercept of 1.93
(1.81–5.67, 95% CI). The mean bias derived from the Altman–
Bland difference plot was 2.4% (0.5–5.2%, 95% CI) with 95% limits
of agreement between 22.5% and 27.3%. Fig. 3B shows good
alignment against the University of Washington LC–MS/MS that
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with correlation coefﬁcient R = 0.94, slope of 1.07 (1.00–1.15, 95%
CI) and an intercept of 3.77 (0.41–7.13, 95% CI). The mean bias was
15.5% (12.8-18.3% 95% CI) with 95% limits of agreement between
8.1% and 39.2%.
The above comparisons indicate that the LIAISON1 XL 1,25-
Dihydroxyvitamin D assay is comparable to LC–MS/MS, which is
considered a higher order method with respect to accuracy.
The LIAISON XL 1,25-Dihydroxyvitamin D assay was also
compared to a commercially available assay (Method A) and
resulted in less than optimal alignment with correlation R = 0.90,
slope of 0.78 (0.69-0.88, 95% CI) and an intercept of 11.38 (6.79–
15.98, 95% CI). The mean bias was 3.1% (0.6%–6.9%, 95% CI) with
95% limits of agreement between 29.4% and 35.7% (Fig. 4). As
shown in Fig. 3C&D, Method A aligned poorly with LC–MS/MS with
Deming regression ﬁt equations of y = 1.26x–12.42 andy = 1.37x–
9.75 when compared to Endocrine Sciences, Laboratory Corpora-
tion of America and University of Washington LC–MS/MS methods,
respectively.
Recovery studies were performed to determine agreement
between expected and measured amounts. Three sets of low and
high samples were mixed at different ratios (3:1, 1:1 and 1:3) and
tested. Table 1 depicts neat, expected, and measured concen-
trations, as well as the percent recovery which was calculated from
the measured and expected values. The assay had a mean recovery
of 93.4%.
3.2. Imprecision and sensitivity
The LIAISON1 XL 1,25-Dihydroxyvitamin D assay was evaluated
for intra-assay imprecision using 2 levels of control and 4 patient
sample pools. Twenty replicates of each of the controls and
4 patient pools were assayed. Inter-assay precision was performed
in 5 assay runs with at least 4 replicates of each of the 2 levels of
control and 4 sample pools. The average intra-assay imprecision
was 3.5%CV (range 1.1-4.7%CV), and inter-assay imprecision
average was 4.5%CV (range 3.4–7.2%CV) (Table 2).
One of the beneﬁcial characteristics of this assay, is its
extremely low imprecision, even at low 1,25-(OH)2D concen-
trations (<5 pg/mL). A LOQ study was performed by measuring
samples with concentrations ranging from 0.342 to 16.5 pg/mL for
10 days. In Fig. 5 EP Evaluator was used to derive the estimated LOQ
(1.57 pg/mL) based on a ﬁtted curve. As shown %CV remain
relatively constant down to sample concentrations as low as 1–
2 pg/mL, while other methods routinely exhibit higher imprecision
especially at concentrations below 15 pg/mL [11–15].
The limit of blank was determined with a total of 10 replicates of
the zero standard. The lowest non-zero concentration that could be
differentiated from zero was calculated as 0.071 pg/mL (95%
conﬁdence) using EP Evaluator1, which is well below the
manufacturer’s claim of 0.35 pg/mL.
3.3. Linearity
One serum sample with a concentration of 217 pg/mL was
chosen. Sample dilutions of 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%,
10% and 0% (neat diluent) were assayed. Diluted sample concen-
trations were measured and compared against calculated values.
The slope of the determined linear regression was 1.02 with
an intercept of 3.779. Average recovery was 107.8% (range
103.2–110.9%)
3.4. Speciﬁcity
Consistent with the design elements enumerated above in
Section 2, the LIAISON XL 1,25-Dihydroxyvitamin D assayexhibits high speciﬁcity for 1,25-(OH)2D with minimal cross-
reactivity against other vitamin D metabolites (25-(OH)D2+3,
24,25-dihydroxyvitamin D3, 25,26-dihydroxyvitamin D3, 3-epi-
25(OH)D3, vitamin D2+3). The lack of correlation between levels
of 25-(OH)D and levels of 1,25-(OH)2D in the samples (Pearson’s
correlation R = 0.15, P = 0.18) supports the speciﬁcity of this assay
(Fig. 6).
Interfering substances were evaluated for the LIAISON XL
1,25-dihydroxyvitamin D assay using the Assurance Interference
Test Kit from Sun Diagnostics New Gloucester, ME. The effect of
hemolysis and icteric and lipemic matrix constituents on
measurement were evaluated based on CLSI EP7-A. No signiﬁcant
interference was observed for triglycerides (3000 mg/dL), hemo-
lysate (500 mg/dL), conjugated bilirubin (20 mg/dL) and unconju-
gated bilirubin (20 mg/mL).
3.5. Reference range
Forty-one ostensibly “normal” patient samples (samples from
healthy volunteers) were assayed to verify the reference range for
serum samples as stated by the manufacturer per package insert
(25.0–86.5 pg/mL). The central 95% interval revealed by the data
for the 41 points assayed was 29.7–88.8 pg/mL. The mean of the
samples tested was 54.4 pg/mL.
4. Conclusions
A novel method was developed for the measurement of
1,25-(OH)2D in biological samples. The unique design of this assay
makes it the ﬁrst fully-automated, small-molecule, sandwich
chemiluminescent assay available and allows for the measure-
ment of a molecule that is present at 1000x lower concentrations
than other quite similar metabolites. The assay is extremely
accurate when compared to LC–MS/MS and has low imprecision,
especially near its limit of quantitation. The assay has a rapid time
to ﬁrst result (65 min) with a throughput of 50–80 tests/hr
thereafter, requires signiﬁcantly smaller sample volume (75 ml),
and performs well in terms of accuracy, imprecision, sensitivity,
linearity and speciﬁcity. The novel assay does not require any pre-
analytical extraction or puriﬁcation steps, which greatly dimin-
ishes its imprecision which was shown to be very low in this
evaluation. Gold-standard methods like LC–MS/MS, however, still
require pre-analytical processing steps which can contribute to
higher imprecision, attributable to extraction in addition to
measurement, rather than just direct measurement.
The assay is robust, and its close alignment with LC–MS/MS
standardization is supported by its performance in the vitamin D
External Quality Assessment Scheme (DEQAS), where multiple
labs perform very well against the target value and with very
small variation between participants (data not shown). van
Helden and Weiskirchen also reported on their evaluation of the
assay and concluded that the novel 1,25-(OH)2D assay is highly
robust [16].
The simplicity of use, and its ability to accurately measure
even small concentrations of 1,25-dihydroxyvitamin D make this
assay a valuable tool for future prospective and retrospective
studies in patients with not only bone and mineral metabolism
diseases, but also in other disease states such as infectious
and autoimmune diseases, diabetes, cancer, cardiovascular ail-
ments, hypertension and complications during pregnancy, where
associations to 25(OH)D have been previously shown, but may
need to be revisited to determine the role of the active form of
vitamin D, 1,25-(OH)2D in subjects/patients with low circulating
25(OH)D.
Fig. 3. 1,25-(OH)2D method comparisons. 78 patient samples were analyzed by 4 different methods: Endocrine Sciences, Laboratory Corporation of America LC–MS/MS,
University of Washington LC–MS/MS, commercially available Method A, and LIAISON1 XL immunoassays. Deming regression (left) and Altman–Bland difference plots with
mean bias and 95% limits of agreement (right) were generated for each method comparison shown.
(A) Total 1,25-(OH)2D was measured with Endocrine Sciences, Laboratory Corporation of America LC–MS/MS as a reference method compared to the LIAISON XL novel assay.
The blue line is the Deming regression with a slope of 0.98 (0.90–1.06, 95% CI) and an intercept of 1.93 (1.81–5.67, 95% CI). Correlation coefﬁcient R =0 .92. The mean bias is
2.4% (0.5–5.2%, 95% CI).
(B) Total 1,25-(OH)2D was measured with University of Washington LC–MS/MS as a reference method compared to the LIAISON XL novel assay. The blue line is the Deming
regression with a slope of 1.07 (1.00–1.15, 95% CI) and an intercept of 3.77 (0.41-7.13, 95% CI). Correlation coefﬁcient R = 0.94. The mean bias is 15.5% (12.8–18.3%, 95% CI).
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(C) Total 1,25-(OH)2D was measured with Endocrine Sciences, Laboratory Corporation of America LC–MS/MS as a reference method compared to Method A. The blue line is
the Deming regression with a slope of 1.26 (1.11–1.41, 95% CI) and an intercept of 12.42 (20.01 to 4.83, 95% CI). Correlation coefﬁcient is R = 0.87. The mean bias is 0.7%
(4.9–3.4%, 95% CI)
(D) Total 1,25-(OH)2D was measured with University of Washington LC–MS/MS as a reference method compared to Method A. The blue line is the Deming regression with a
slope of 1.37 (1.24–1.50, 95% CI) and an intercept of 9.75 (15.58 to -3.92 95% CI). Correlation coefﬁcient is R = 0.90. The mean bias is 12.4% (8.8–16.0%, 95% CI).
Fig. 4. Total 1,25-(OH)2D was measured with Method A and compared to the LIAISON XL novel assay. The blue line is the Deming regression with a slope of 0.78 (0.69–0.88,
95% CI) and an intercept of 11.38 (6.79–15.98, 95% CI). Correlation coefﬁcient R = 0.90. The mean bias is 3.1% (29.4–35.7%, 95% CI). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Recovery of 1,25-(OH)2D in serum using the novel 1,25-(OH)2D assay. Three separate specimens (low samples) were assayed to determine circulating levels of 1,25-(OH)2D
using the novel assay. Each sample was mixed with different concentrations of another patient sample (high sample) through sample mixing at ratios of 3:1, 1:1 and 1:3 (low
sample: high sample) and assayed. The high samples were also assayed neat. Percent recoveries were calculated from measured and expected values.
Expected Measured Recovery
Deﬁned Concentration pg/mL pg/mL %
Low Sample 1 (LS1) 17.4 17.4
0.75 LS1:0.25 HS1 54.6 51.4 94.2%
0.50 LS1:0.50 HS1 91.7 86.3 94.1%
0.25 LS1:0.75 HS1 128.9 122.3 94.9%
High Sample 1 (HS1) 166.0 166.0
Low Sample 2 (LS2) 17.8 17.8
0.75 LS2:0.25 HS2 62.4 58.4 93.7%
0.50 LS2:0.50 HS2 106.9 95.7 89.5%
0.25 LS2:0.75 HS2 151.5 139.7 92.2%
High Sample 2 (HS2) 196.0 196.0
Low Sample 3 (LS3) 21.8 21.8
0.75 LS3:0.25 HS3 59.1 54.7 92.6%
0.50 LS3:0.50 HS3 96.4 91.9 95.3%
0.25 LS3:0.75 HS3 133.7 126.3 94.5%
High Sample 3 (HS3) 171.0 171.0
Table 2
Intra—and Inter-assay imprecision for the novel 1,25-(OH)2D assay. The 1,25-
(OH)2D assay was evaluated for intra-assay imprecision using 2 levels of control and
4 patient sample pools. Twenty replicates of each of the controls and 4 patient pools
were assayed. The inter-assay imprecision was performed in 5 assay runs on
different days with at least 4 replicates of each of the 2 levels of control and
4 sample pools.
Intra-assay Inter-assay
Sample N Mean SD CV Mean SD CV
(pg/mL) (pg/mL) % (pg/mL) (pg/mL) %
Control 1 20 25.5 1.06 4.2 23.2 0.78 3.4
Control 2 20 94.9 4.48 4.7 105.7 3.99 3.8
Patient Pool 1 20 25.8 1.06 4.1 27.6 1.05 3.8
Patient Pool 2 20 42.3 0.45 1.1 44.5 2.00 4.5
Patient Pool 4 20 91.8 3.86 4.2 89.0 6.37 7.2
Patient Pool 5 20 180.4 4.50 2.5 178.5 8.10 4.5
Fig. 5. Sensitivity: Limit of Quantitation (LOQ). Eight samples around the limit of
quantitation indicated by the manufacturer (5 pg/mL) were measured for 10 days
and %CVs were determined. EP Evaluator1was used to estimate the LOQ, the point
at which the ﬁtted curve crosses the 20% CV line. The estimated LOQ is 1.57 pg/mL.
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Fig. 6. Measurements of 25-(OH)D and 1,25-(OH)2D for each sample are displayed
by scatter plot. Pearson’s correlation analysis showed no signiﬁcant correlation
between levels of 25-(OH)D and 1,25-(OH)2D (R = 0.15, P = 0.18).
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The method was presented at the 2014 IFCC World Lab in
Instanbul, Turkey.
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